Statin use and mortality in rheumatoid arthritis: A general population-based cohort study

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1315-1320

  Schoenfeld, Sara R ^a   Lu, Leo ^a,b   Rai, Sharan K ^c   Seeger, John D ^d   Zhang, Yuqing ^b   Choi, Hyon K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; UNITED KINGDOM; ARTHRITIS, RHEUMATOID; CAUSE OF DEATH;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROPENSITY SCORE;

EID: 84940186683     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207714     Document Type: Article

References (40)

1. Ogdie A, Haynes K, Troxel AB, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: A longitudinal cohort study. Ann Rheum Dis 2014;73:149-53.
2. Bjornadal L, Baecklund E, Yin L, et al. Decreasing mortality in patients with rheumatoid arthritis: Results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002;29:906-12.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005;52:402-11.
4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
5. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
6. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293-9.
7. Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
8. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
9. [No authors listed]. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. [No authors listed]. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
12. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
13. Alehagen U, Benson L, Edner M, et al. Association between use of statins and outcomes in heart failure with reduced ejection fraction: A prospective propensity score matched cohort study of 21, 864 patients in the Swedish Heart Failure Registry. Circ Heart Fail 2015;8:252-60.
14. Cholesterol Treatment Trialists' (CTT) Collaborators Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
15. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
17. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy? Arthritis Rheum 2006;54:393-407.
18. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
19. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
20. Peters MJ, Nurmohamed MT. Cardiovascular risk management in rheumatoid arthritis: Are we still waiting for the first step? Arthritis Res Ther 2013;15:111.
21. Kitas GD, Nightingale P, Armitage J, et al. Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA). Ann Rheum Dis 2015;74(Suppl 2):688.
22. Simon C. Overview of the GP Contract. Innov AiT 2008;1:134-9.
23. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7.
24. Stuart-Buttle CD, Read JD, Sanderson HF, et al. A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996:75-9.
25. Epic. THIN data from EPIC: A guide for researchers. London: EPIC, 2007.
26. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
27. Thomas SL, Edwards CJ, Smeeth L, et al. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum 2008;59:1314-21.
28. Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
29. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005;14:465-76.
30. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
31. Morris R, Carstairs V. Which deprivation? A comparison of selected deprivation indexes. J Public Health Med 1991;13:318-26.
32. Townsend P, Phillimore P, Beattie A. Health and deprivation: Inequality and the North. London: Croom Helm, 1988.
33. Surmer T, Rothman KJ, Avorn J, et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol 2010;172:843-54.
34. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
35. Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: A cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol 2013;62:717-29.
36. Sheng X, Murphy MJ, Macdonald TM, et al. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012;39:32-40.
37. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64:2836-46.
38. Hermann F, Forster A, Chenevard R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005; 45:461-4.
39. Van Doornum, S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:1571-5.
40. Rollefstad S, Ikdahl E, Hisdal J, et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: The rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Arthritis Rheum 2015;67:1718-28.